We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Model Outperforms Clinicians in Rare Disease Detection

By LabMedica International staff writers
Posted on 04 Mar 2026

Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. More...

Many conditions present with heterogeneous signs that overlap with common disorders, leading to repeated referrals, misdiagnosis, and unnecessary procedures. For many patients, time to a confirmed diagnosis can exceed five years. A new study now shows that an artificial intelligence (AI) system can outperform experienced clinicians in identifying rare diseases earlier and more accurately.

A team led by researchers at Shanghai Jiao Tong University and affiliated institutions has developed DeepRare, an agentic framework for rare-disease prioritization and diagnosis. Rather than relying on a single model, the system coordinates 40 specialized digital tools to analyze diverse inputs, including a patient’s DNA, official medical databases, and handwritten clinical notes. A central AI host orchestrates these components to synthesize evidence and converge on a diagnosis with traceable reasoning.

DeepRare was first evaluated on 6,401 clinical cases with known outcomes. Using the same symptom and DNA information available to the original clinicians years earlier, the system could have identified the correct condition earlier in the diagnostic process. In this retrospective benchmark, it also outperformed 15 existing diagnostic systems.

A subsequent head-to-head assessment tested DeepRare against physicians on 163 difficult cases. Five experienced doctors, each with more than a decade of practice, received the same data as the system. DeepRare achieved a 64.4% top-1 diagnostic accuracy on the first attempt, compared with 54.6% for the physicians.

Even when not exactly correct on the first try, the model’s Recall@3 indicated that the right diagnosis was usually among its top three suggestions. Ten rare-disease specialists reviewed the system’s step-by-step reasoning and agreed with its logic 95.4% of the time. The findings were detailed in a study published in Nature on February 18, 2026.

"DeepRare is one of the first computational models to surpass the diagnostic performance of expert physicians in the complex task of rare-disease phenotyping and diagnosis," stated the study's authors. "Our work not only advances rare disease diagnosis but also demonstrates how the latest powerful large-language-model-driven agentic systems can reshape current clinical workflows."

Related Links:
Shanghai Jiao Tong University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Urine Analyzer
respons® UDS100
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.